Philadelphia Trust Co. Sells 10,346 Shares of Illumina, Inc. (NASDAQ:ILMN)

Philadelphia Trust Co. reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 45.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,195 shares of the life sciences company's stock after selling 10,346 shares during the quarter. Philadelphia Trust Co.'s holdings in Illumina were worth $1,698,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. abrdn plc raised its position in shares of Illumina by 764.9% during the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company's stock worth $47,206,000 after purchasing an additional 299,827 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Illumina in the third quarter valued at $29,558,000. International Assets Investment Management LLC boosted its holdings in shares of Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company's stock valued at $6,711,000 after acquiring an additional 32,672 shares during the period. Victory Capital Management Inc. grew its position in Illumina by 5.9% in the 4th quarter. Victory Capital Management Inc. now owns 122,743 shares of the life sciences company's stock worth $17,091,000 after purchasing an additional 6,827 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Illumina by 49.0% during the fourth quarter. BNP Paribas Financial Markets now owns 275,762 shares of the life sciences company's stock worth $38,397,000 after buying an additional 90,634 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Down 0.8 %

Shares of NASDAQ:ILMN traded down $0.92 on Tuesday, reaching $107.61. The company had a trading volume of 1,611,694 shares, compared to its average volume of 1,718,640. The stock has a market capitalization of $17.14 billion, a P/E ratio of -13.20 and a beta of 1.20. The stock has a 50-day moving average price of $124.04 and a 200 day moving average price of $126.91. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $213.91. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company earned $0.08 EPS. The company's revenue for the quarter was down 1.0% on a year-over-year basis. On average, equities analysts expect that Illumina, Inc. will post 0.87 EPS for the current year.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company's stock, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.17% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on ILMN. StockNews.com upgraded Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, May 11th. Scotiabank decreased their target price on shares of Illumina from $185.00 to $176.00 and set a "sector outperform" rating for the company in a research report on Monday, May 6th. OTR Global reissued a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Barclays upped their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research note on Wednesday, April 10th. Finally, Stephens reiterated an "overweight" rating and set a $170.00 price objective on shares of Illumina in a research note on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $164.65.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.